Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

Functional consequences of high glucose culture on adoptive T cell therapies for cancer

Award Number: F30CA298391
ORGANIZATION: NATIONAL CANCER INSTITUTE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: FELLOWSHIP/SCHOLARSHIP/STUDENT LOANS
PERIOD OF PERFORMANCE START DATE: 04/01/2025
PERIOD OF PERFORMANCE END DATE: 03/31/2029

Group Awards By:

View Award Description

Functional consequences of high glucose culture on adoptive T cell therapies for cancer - PROJECT SUMMARY/ABSTRACT Adoptive cell therapy (ACT) is a form of immunotherapy in which T cells are isolated from a patient, genetically modified, expanded in vitro and then transferred back to the patient to initiate antitumor immunity. Chimeric antigen receptor T cells (CAR-T) is a form of ACT where the T cells are modified to contain a tumor specific receptor (CAR). CAR-T cells have demonstrated clinical success particularly in hematological malignancies, however, efficacy in solid tumors has remained poor and many patients ultimately relapse. The in vitro expansion step of CAR-T cell therapy is critical for generating enough cells to transfer back to the patient, but the transfer of cells from a patient to an in vitro environment and then back to the patient requires T cells to be metabolically flexible. Cell culture media has been well demonstrated to induce metabolic dysfunction on T cells and alter their effector function. Healthy blood glucose is approximately 5mM, however, the in vitro expansion media contains nearly 10x blood glucose levels to favor proliferation. Preliminary data suggests that T cells cultured in high levels of glucose are less responsive to T cell receptor (TCR) stimulation demonstrating a reduction in IFNγ and TNFα when stimulated with αCD3/αCD28. Additionally, adoptive transfer of tumor-specific T cells cultured in 55mM glucose into B16F10 tumor-bearing mice demonstrate reduced tumor control compared T cells cultured in lower glucose concentrations (11mM). Increases in both intracellular and extracellular glucose have been shown to affect glycosylation of cellular proteins. Glycosylation is an important post-translational modification that impacts transport, signaling and localization of proteins. Thus, we wondered if intracellular glycosylation mark, O-linked β-N-acetylglucosamine (O-GlcNAc) would be changed following culture in higher levels of glucose. Indeed, we see elevated proteome wide O-GlcNAc as we increase glucose in culture media. O-GlcNAc is added to serine and threonine residues by the enzyme O-GlcNAc transferase (OGT). Given the role of serine’s and threonine’s in phosphorylation, we assessed whether T cell signaling would be altered by exposure to high levels of glucose in culture. We restimulated the cells using a time course to assess phosphorylation of downstream T cell signaling intermediates. Our preliminary data suggests delayed induction and reduced maximal induction of p-Erk, p-S6 and p-Akt. Thus, we hypothesize that high levels of glucose in cell culture media alter T cell signaling pathways by blocking critical phosphorylation sites of signaling proteins with O-GlcNAc. We will test this hypothesize by (1) identifying what cellular proteins are differentially O-GlcNAcylated and whether inhibiting O- GlcNAcylation restores cytokine production, antitumor immunity and T cell signaling and (2) whether these findings translate to human models using CAR-T cells. Findings from these studies will provide mechanistic understanding of how excess glucose in the culture media contributes to protein glycosylation and whether this is linked to decreased effector function. We will translate these findings to CAR-T cells. The insights from this study will provide rationale for optimizing culture media formulations to enhance patient response to adoptive cell therapies.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2026 ( Subtotal = $55,114 )
2026	2026	UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION	4200 FIFTH AVENUE	PITTSBURGH	PA	15260	ALLEGHENY	USA	Cancer Research Manpower	000	2	4/9/2026	NON-COMPETING CONTINUATION	$55,114
														Subtotal = $55,114

Issue Date FY: 2025 ( Subtotal = $54,538 )
2025	2025	UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION	4200 FIFTH AVENUE	PITTSBURGH	PA	15260	ALLEGHENY	USA	Cancer Research Manpower	000	1	3/17/2025	NEW	$53,974
2025	2025	UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION	4200 FIFTH AVENUE	PITTSBURGH	PA	15260	ALLEGHENY	USA	Cancer Research Manpower	001	1	3/17/2025	NEW	$0
2025	2025	UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION	4200 FIFTH AVENUE	PITTSBURGH	PA	15260	ALLEGHENY	USA	Cancer Research Manpower	002	1	5/22/2025	NEW	$564
														Subtotal = $54,538

Grand Total All Awards = $109,652

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Functional consequences of high glucose culture on adoptive T cell therapies for cancer

Award Number: F30CA298391

ORGANIZATION: NATIONAL CANCER INSTITUTE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: FELLOWSHIP/SCHOLARSHIP/STUDENT LOANS

PERIOD OF PERFORMANCE START DATE: 04/01/2025

PERIOD OF PERFORMANCE END DATE: 03/31/2029

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer